Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

US clinical-stage biotech Vigil Neuroscience (Nasdaq: VIGL) today announced a disappointing update on the Phase II IGNITE ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Vigil on Wednesday said it is ending a Phase 2 study of iluzanebart in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP, after the drug showed no ...

Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

France's Sanofi has agreed to buy US-based Blueprint Medicines Corp. for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest health care deal in Europe this ...

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?